Vers un diagnostic et un traitement précoces et affinés du cancer

!!!!!!!!!!!!! !!!!!!!!!!!
!
!
Paris, le 30 janvier 2017
!
!"#$%&'%()*+',$-).%"-%&'%-#*)-"/"'-%0#1.,."$%"-%*22)'1$%(&%.*'."#%
%
3415&)0"%("%6*-#)7)*%6*-"#8)')9:#1.;,-<%0#,2"$$"&#%"'%=),8,+)"%."88&8*)#"%"-%,'.,8,+)"%>%84?')@"#$)-1%
6*#)$% A"$.*#-"$% "-% .;"#.;"&$"% *&% $")'% (&% (10*#-"/"'-% B%C//&',8,+)"<% )'2".-),8,+)"% "-%
;1/*-,8,+)"%D%("%84C'$-)-&-%E".F"#%G'2*'-$%H*8*("$%I%J"'-#"%("%/1(".)'"%/,81.&8*)#"%K?')@"#$)-1%
6*#)$%A"$.*#-"$L%C'$"#/%L%JEMN%L%O69P6Q% *%0&=8)1%&'%*#-).8"%(*'$%8*%#"@&"%PLOS! One%8"% R% S*'@)"#%
("#')"#T%J"--"% 0&=8).*-),'% /*#5&"%&'"%*@*'.1"%-#U$%'"--"%(*'$%8"$%-".;')5&"$%(4)$,8"/"'-%"-%("%
.*#*.-1#)$*-),'%/,81.&8*)#"%("$%."88&8"$%-&/,#*8"$%.)#.&8*'-"$%0"#/"--*'-%8*%(1-".-),'%0#1.,."%("%
84)'@*$),'%-&/,#*8"T%
%
"#$%!&'()!*$!+,-!---!./(#$0(1!%0)!23&$24/253)!$.!6-789!'0!'(44$!%/.42$!'$!%0.%$2!$)4!&'()!:($!;0<05)!
(.$!:($)45/.!*$!)0.43!&(='5:($>!?0!&23%/%543! *(!*50@./)45%!$4! *$! '0!&25)$!$.!%A02@$! 4A320&$(45:($!
%/.)454($.4!*$)!B0%4$(2)!&2/./)45:($)!$))$.45$')!*0.)!'$)!&/))5=5'543)!*$!23<5))5/.!*(!&045$.4>!C0425D50!
C04$2'5.5EF23%A/4!$4!)/.!3:(5&$!/.4!<5)!0(!&/5.4!(.$!<34A/*$!*G5)/'$<$.4!&02!'0!405''$!*$)!%$''('$)!
4(</20'$)! H! 42/&A/='0)45:($)! IJKLMN! %0&0='$! *$! *34$%4$2! 42O)! &23%/%$<$.4! *$)! %$''('$)! 202$)!
%52%('0.4$)! IPQPN! &23)$.4$)! *0.)! '$! )0.@! $4! 0../.R0.4! 42O)! $.! 0</.4! 'G0&&02545/.! *G(.$! 4(<$(2!
%0.%32$()$>!
!
P$)! %$''('$)! )/.4! *$! *$(1! 4S&$)!T! '$)! %$''('$)! 4(</20'$)! %52%('0.4$)! IPMPN! $4! '$)! <5%2/3<=/'$)!
4(</20(1! %52%('0.4)! IPMUN>! ?G(.! *$)! &2/='O<$)! 4$%A.5:($)! *$! '0! %/''$%4$! *$)! PMP! $)4! '53! V! '$(2!
B20@5'543>! W29! 0B5.! *$! '$)! (45'5)$2! *$! B0R/.! /&45<0'$9! 5'! $)4! *$! &2$<5O2$! 5<&/240.%$! *$! &/(#/52! '$)!
23%(&32$2!*0.)!'$!)0.@9!*$!B0R/.!A0(4$<$.4!)$.)5='$9!$4!)0.)!&$24$!*$!:(0'543!*$!%$)!%$''('$)9!0B5.!*$!
&2/%3*$2!V!(.$!34(*$!</'3%('052$!$BB5%0%$>!
!
P$44$! 34(*$!*3%254! (.! ./(#$0(! &2/4/%/'$! &/(2! $.25%A52! '$)! PMP! #5#0.4$)! *(! )0.@! V! 'X05*$! *$! '0!
<34A/*$! JKLM!$4! B0#/25)$2! %$44$! %/''$%4$>! Y!Nous% avons% évalué% l’impact% de% cette% méthode%
d'enrichissement%sur%l'expression%antigénique,%la%structure%du%cytosquelette,%la%viabilité%cellulaire%des%
cellules% tumorales% vivantes% et% leur% capacité% à% croitre% en% culture.% Nous% avons% également% analysé% la%
performance% in% vitro% d'ISET% pour% recueillir% des% cellules% cancéreuses% rarissimes% fixées% et% vivantes%
intactes%Z!*3%'02$!'$!C2/B$))$(2!C04$2'5.5EF23%A/4>!!
!
?$)! 23)('404)! /=4$.()! </.42$.4! :($! '0! <34A/*$! JKLM!&$2<$4! *G044$5.*2$! (.! 42O)! A0(4! .5#$0(! *$!
&23%5)5/.!*0.)!'$!*50@./)45%!*$)!%0.%$2)!)(2!(.!42O)!B05='$!3%A0.45''/.!)0.@(5.>!L.!$BB$49!5'!$)4!&/))5='$!
*$!*34$%4$2!*$)!%$''('$)!4(</20'$)!B513$)!$4!#5#0.4$)!)(2!(.!)5<&'$!&23'O#$<$.4!*$!7-!<'!*$!)0.@>!?0!
)$.)5=5'543!*$!%$)!4$)4)!$)4!$1%$''$.4$!0#$%!(.!)$(5'!*$!*34$%45/.!*G(.$!%$''('$!4(</20'$!*0.)!7-!<'!*$!
)0.@! *0.)!,+! V! 7--! [! *$)! %0)>! P$! )$(5'! $142\<$<$.4! 3'$#3! $)4! <05.4$.(! '/2):($! '$! &'0)<0! $)4!
2$%($5''5!0#0.4!'X5)/'$<$.4!*$)!%$''('$)!4(</20'$)>!
!
C02! 05''$(2)9! (.$! 0.0'S)$! %/<&02045#$! *$! 'G"]^! *$)! %$''('$)! 4(</20'$)! 0! 343! $BB$%4(3$! &02!!
)3:($.R0@$! V! A0(4! *3=549! 0#0.4! $4! 0&2O)! '$(2! 5)/'$<$.4! *(! )0.@! $4! $.! %('4(2$>! P$44$! 0.0'S)$!
@3.345:($! &$2<$4420! *G0BB5.$2! $.%/2$! '$)! 0)&$%4)! *50@./)45%)! $4! '0! <5)$! $.! &'0%$! 20&5*$! *G(.!

2
&2/4/%/'$! 4A320&$(45:($! 0*0&43! V! %A0:($! &045$.4>! L.B5.9! '$! B054! *G0#/52! 23())5! V! 5)/'$2! %$)! %$''('$)!
4(</20'$)!#5#0.4$)!&(5)!V!'$)!%('45#$2!in%vitro!/(#2$.4!*$!./<=2$()$)!&$2)&$%45#$)!)(2!'$)!230%45/.)!
5<<(.54052$)!*$!'G/[email protected])<$!B0%$!0(!%0.%$2>!!
!
Y!En%effet,%la%culture%in%vitro%des%cellules%cancéreuses%permettra%à%l’avenir%de%tester%des%thérapies%en%
amont%afin%de%savoir%si%elles%peuvent%agir%sur%ces%cancers.%Elle%pourra%permettre%également%d’utiliser%
les% cellules% cancéreuses% circulantes% cultivées% pour% stimuler% la% réponse% immunitaire% de% l’organisme%
contre% le% cancer,% une% perspective% porteuse% de% grand% espoir% dans% le% combat% contre% cette% maladieZ!
%/.%'(4!'$!C2/B$))$(2!C04$2'5.5EF23%A/4>!
!
%
%
%
N,&#."%%
V".;').*8%C'$)+;-$%)'-,%P)+;8W%N"'$)-)@"%C$,8*-),'%*'(%H,8".&8*#%J;*#*.-"#)7*-),'%,2%X)Y"(%*'(%3)@"%
J)#.&8*-)'+%V&/,#%J"88$%2,#%G*#8W%A"-".-),'%,2%V&/,#%C'@*$),'<%
;--0ZLL(YT(,)T,#+L[\T[]^[LS,&#'*8T0,'"T\[R_`a^%%
K/&A5$!?0@$479!?(%5'$!F2/.%S7969!_0450!`/2<5@/)79!]0'50!U>!]A5.@20+9!a045<0!F$.U/A0<$*69!MA5$22S!
P0&5/*69!U0@.$!W)4$20)b9!?0(2$.4!a025.$''5b9!K4$&A$.!c0%d)/.+9!e!C0425D50!C04$2'5.5EF23%A/46!
%
7T!Q02$%$'')!]50@./)45%)9!C025)9!a20.%$!!
6T!f.543!J^KLQU!f7787!IL:!7+N9!a0%('43!*$!U3*$%5.$!C025)!]$)%024$)9!C025)9!a20.%$!!
+T!MA$2</!a5)A$2!K%5$.45B5%9!K/(4A!K0.!a20.%5)%/9!P0'5B/2.509!fK"!7+!!
bT!a0)4$25)!K"9!g$.$#09!Kh54D$2'0.*!
Contact presse
Pierre-Yves Clausse
01 76 53 17 98
[e-mail]